PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2020
LYON, France , April 06, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F
LYON, France and CAMBRIDGE, Mass. , March 19, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed its 2019
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2019
Conference call and webcast on Tuesday, March 17 at 1:30 pm CET/8:30 am ET More than two-thirds of the expected number of patients have been enrolled in the TRYbeCA‑1 Phase 3 clinical trial Cash position of €73.2 million ( $82.2 million ) at the end of 2019 LYON, France and CAMBRIDGE, Mass.
View HTML
Toggle Summary ERYTECH Announces the Appointment of Dr. Melanie Rolli to its Board of Directors
LYON, France and CAMBRIDGE, Mass. , March 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the appointment of Melanie
View HTML
Toggle Summary ERYTECH to Host Fourth Quarter and Full Year 2019 Conference Call and Business Update
LYON, France , March 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – February 29, 2020
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , March 06, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary ERYTECH to Present at Cowen and Company 40th Annual Health Care Conference
LYON, France and CAMBRIDGE, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen ,
View HTML
Toggle Summary ERYTECH Enters Into Strategic Supply Partnership with the German Red Cross Blood Donor Service
Second European source of donor red blood cells secured in preparation for expanded production of red blood cell-based therapeutics LYON, France and CAMBRIDGE, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2020
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer Trial in Progress Poster selected for inclusion in Poster Walk LYON, France and CAMBRIDGE, Mass. , Jan. 24, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage
View HTML
Top